Strategies to Avoid Killing by Human Neutrophils
Staphylococcus epidermidis is a leading nosocomial pathogen. In contrast to its more aggressive relative S. aureus, it causes chronic rather than acute infections. In highly virulent S. aureus, phenol-soluble modulins (PSMs) contribute significantly to immune evasion and aggressive virulence by their strong ability to lyse human neutrophils. Members of the PSM family are also produced by S. epidermidis, but their role in immune evasion is not known. Notably, strong cytolytic capacity of S. epidermidis PSMs would be at odds with the notion that S. epidermidis is a less aggressive pathogen than S. aureus, prompting us to examine the biological activities of S. epidermidis PSMs. Surprisingly, we found that S. epidermidis has the capacity to produce PSMδ, a potent leukocyte toxin, representing the first potent cytolysin to be identified in that pathogen. However, production of strongly cytolytic PSMs was low in S. epidermidis, explaining its low cytolytic potency. Interestingly, the different approaches of S. epidermidis and S. aureus to causing human disease are thus reflected by the adaptation of biological activities within one family of virulence determinants, the PSMs. Nevertheless, S. epidermidis has the capacity to evade neutrophil killing, a phenomenon we found is partly mediated by resistance mechanisms to antimicrobial peptides (AMPs), including the protease SepA, which degrades AMPs, and the AMP sensor/resistance regulator, Aps (GraRS). These findings establish a significant function of SepA and Aps in S. epidermidis immune evasion and explain in part why S. epidermidis may evade elimination by innate host defense despite the lack of cytolytic toxin expression. Our study shows that the strategy of S. epidermidis to evade elimination by human neutrophils is characterized by a passive defense approach and provides molecular evidence to support the notion that S. epidermidis is a less aggressive pathogen than S. aureus.
Vyšlo v časopise:
Strategies to Avoid Killing by Human Neutrophils. PLoS Pathog 6(10): e32767. doi:10.1371/journal.ppat.1001133
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1001133
Souhrn
Staphylococcus epidermidis is a leading nosocomial pathogen. In contrast to its more aggressive relative S. aureus, it causes chronic rather than acute infections. In highly virulent S. aureus, phenol-soluble modulins (PSMs) contribute significantly to immune evasion and aggressive virulence by their strong ability to lyse human neutrophils. Members of the PSM family are also produced by S. epidermidis, but their role in immune evasion is not known. Notably, strong cytolytic capacity of S. epidermidis PSMs would be at odds with the notion that S. epidermidis is a less aggressive pathogen than S. aureus, prompting us to examine the biological activities of S. epidermidis PSMs. Surprisingly, we found that S. epidermidis has the capacity to produce PSMδ, a potent leukocyte toxin, representing the first potent cytolysin to be identified in that pathogen. However, production of strongly cytolytic PSMs was low in S. epidermidis, explaining its low cytolytic potency. Interestingly, the different approaches of S. epidermidis and S. aureus to causing human disease are thus reflected by the adaptation of biological activities within one family of virulence determinants, the PSMs. Nevertheless, S. epidermidis has the capacity to evade neutrophil killing, a phenomenon we found is partly mediated by resistance mechanisms to antimicrobial peptides (AMPs), including the protease SepA, which degrades AMPs, and the AMP sensor/resistance regulator, Aps (GraRS). These findings establish a significant function of SepA and Aps in S. epidermidis immune evasion and explain in part why S. epidermidis may evade elimination by innate host defense despite the lack of cytolytic toxin expression. Our study shows that the strategy of S. epidermidis to evade elimination by human neutrophils is characterized by a passive defense approach and provides molecular evidence to support the notion that S. epidermidis is a less aggressive pathogen than S. aureus.
Zdroje
1. OttoM
2008 Staphylococcal biofilms. Curr Top Microbiol Immunol 322 207 228
2. OttoM
2009 Staphylococcus epidermidis - the ‘accidental’ pathogen. Nat Rev Microbiol 7 555 567
3. NauseefWM
2007 How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 219 88 102
4. CostertonJW
StewartPS
GreenbergEP
1999 Bacterial biofilms: a common cause of persistent infections. Science 284 1318 1322
5. KocianovaS
VuongC
YaoY
VoyichJM
FischerER
2005 Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest 115 688 694
6. VuongC
VoyichJM
FischerER
BraughtonKR
WhitneyAR
2004 Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell Microbiol 6 269 275
7. FosterTJ
2005 Immune evasion by staphylococci. Nat Rev Microbiol 3 948 958
8. RooijakkersSH
van KesselKP
van StrijpJA
2005 Staphylococcal innate immune evasion. Trends Microbiol 13 596 601
9. WoodinA
1970 Staphylococcal leukocidin.
MontjeT
KadisS
AjlS
Microbial toxins New York Academic Press, Inc 327 355
10. WangR
BraughtonKR
KretschmerD
BachTH
QueckSY
2007 Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13 1510 1514
11. McKevittAI
BjornsonGL
MauracherCA
ScheifeleDW
1990 Amino acid sequence of a deltalike toxin from Staphylococcus epidermidis. Infect Immun 58 1473 1475
12. MehlinC
HeadleyCM
KlebanoffSJ
1999 An inflammatory polypeptide complex from Staphylococcus epidermidis: isolation and characterization. J Exp Med 189 907 918
13. YaoY
SturdevantDE
OttoM
2005 Genomewide analysis of gene expression in Staphylococcus epidermidis biofilms: insights into the pathophysiology of S. epidermidis biofilms and the role of phenol-soluble modulins in formation of biofilms. J Infect Dis 191 289 298
14. GillSR
FoutsDE
ArcherGL
MongodinEF
DeboyRT
2005 Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J Bacteriol 187 2426 2438
15. HajjarAM
O'MahonyDS
OzinskyA
UnderhillDM
AderemA
2001 Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 166 15 19
16. KlebanoffSJ
KazaziF
Van VoorhisWC
SchlechteKG
1994 Activation of the human immunodeficiency virus long terminal repeat in THP-1 cells by a staphylococcal extracellular product. Proc Natl Acad Sci U S A 91 10615 10619
17. LilesWC
ThomsenAR
O'MahonyDS
KlebanoffSJ
2001 Stimulation of human neutrophils and monocytes by staphylococcal phenol-soluble modulin. J Leukoc Biol 70 96 102
18. HashimotoM
TawaratsumidaK
KariyaH
KiyoharaA
SudaY
2006 Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J Immunol 177 3162 3169
19. FaurschouM
BorregaardN
2003 Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 5 1317 1327
20. HancockRE
DiamondG
2000 The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8 402 410
21. LaiY
VillaruzAE
LiM
ChaDJ
SturdevantDE
2007 The human anionic antimicrobial peptide dermcidin induces proteolytic defence mechanisms in staphylococci. Mol Microbiol 63 497 506
22. LiM
LaiY
VillaruzAE
ChaDJ
SturdevantDE
2007 Gram-positive three-component antimicrobial peptide-sensing system. Proc Natl Acad Sci U S A 104 9469 9474
23. HerbertS
BeraA
NerzC
KrausD
PeschelA
2007 Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog 3 e102
24. LiM
ChaDJ
LaiY
VillaruzAE
SturdevantDE
2007 The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol 66 1136 1147
25. PeschelA
OttoM
JackRW
KalbacherH
JungG
1999 Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274 8405 8410
26. PeschelA
JackRW
OttoM
CollinsLV
StaubitzP
2001 Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 193 1067 1076
27. VoyichJM
BraughtonKR
SturdevantDE
WhitneyAR
Said-SalimB
2005 Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 175 3907 3919
28. ZhangYQ
RenSX
LiHL
WangYX
FuG
2003 Genome-based analysis of virulence genes in a non-biofilm-forming Staphylococcus epidermidis strain (ATCC 12228). Mol Microbiol 49 1577 1593
29. QueckSY
Jameson-LeeM
VillaruzAE
BachTH
KhanBA
2008 RNAIII-Independent Target Gene Control by the agr Quorum-Sensing System: Insight into the Evolution of Virulence Regulation in Staphylococcus aureus. Mol Cell 32 150 158
30. VuongC
DurrM
CarmodyAB
PeschelA
KlebanoffSJ
2004 Regulated expression of pathogen-associated molecular pattern molecules in Staphylococcus epidermidis: quorum-sensing determines pro-inflammatory capacity and production of phenol-soluble modulins. Cell Microbiol 6 753 759
31. MellorIR
ThomasDH
SansomMS
1988 Properties of ion channels formed by Staphylococcus aureus delta-toxin. Biochim Biophys Acta 942 280 294
32. TalbotJC
ThiaudiereE
VincentM
GallayJ
SiffertO
2001 Dynamics and orientation of amphipathic peptides in solution and bound to membranes: a steady-state and time-resolved fluorescence study of staphylococcal delta-toxin and its synthetic analogues. Eur Biophys J 30 147 161
33. CogenAL
YamasakiK
SanchezKM
DorschnerRA
LaiY
2010 Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin. J Invest Dermatol 130 192 200
34. OttoM
O'MahoneyDS
GuinaT
KlebanoffSJ
2004 Activity of Staphylococcus epidermidis phenol-soluble modulin peptides expressed in Staphylococcus carnosus. J Infect Dis 190 748 755
35. VuongC
KocianovaS
YaoY
CarmodyAB
OttoM
2004 Increased colonization of indwelling medical devices by quorum-sensing mutants of Staphylococcus epidermidis in vivo. J Infect Dis 190 1498 1505
36. VuongC
GerkeC
SomervilleGA
FischerER
OttoM
2003 Quorum-sensing control of biofilm factors in Staphylococcus epidermidis. J Infect Dis 188 706 718
37. LeY
MurphyPM
WangJM
2002 Formyl-peptide receptors revisited. Trends Immunol 23 541 548
38. SomervilleGA
CockayneA
DurrM
PeschelA
OttoM
2003 Synthesis and deformylation of Staphylococcus aureus delta-toxin are linked to tricarboxylic acid cycle activity. J Bacteriol 185 6686 6694
39. KretschmerD
GleskeA
RautenbergM
WangR
KoberleM
2010 Human formyl peptide receptor 2 (FPR2/ALX) senses highly pathogenic Staphylococcus aureus. Cell Host Microbe. In press
40. KobayashiY
2008 The role of chemokines in neutrophil biology. Front Biosci 13 2400 2407
41. NizetV
2007 Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 120 13 22
42. LaiY
Di NardoA
NakatsujiT
LeichtleA
YangY
2009 Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 15 1377 1382
43. VuongC
OttoM
2002 Staphylococcus epidermidis infections. Microbes Infect 4 481 489
44. KongKF
VuongC
OttoM
2006 Staphylococcus quorum sensing in biofilm formation and infection. Int J Med Microbiol 296 133 139
45. RogersDE
TompsettR
1952 The survival of staphylococci within human leukocytes. J Exp Med 95 209 230
46. YaoY
VuongC
KocianovaS
VillaruzAE
LaiY
2006 Characterization of the Staphylococcus epidermidis Accessory-Gene Regulator Response: Quorum-Sensing Regulation of Resistance to Human Innate Host Defense. J Infect Dis 193 841 848
47. GreshamHD
LowranceJH
CaverTE
WilsonBS
CheungAL
2000 Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol 164 3713 3722
48. ShompoleS
HenonKT
LiouLE
DziewanowskaK
BohachGA
2003 Biphasic intracellular expression of Staphylococcus aureus virulence factors and evidence for Agr-mediated diffusion sensing. Mol Microbiol 49 919 927
49. MackD
NedelmannM
KrokotschA
SchwarzkopfA
HeesemannJ
1994 Characterization of transposon mutants of biofilm-producing Staphylococcus epidermidis impaired in the accumulative phase of biofilm production: genetic identification of a hexosamine-containing polysaccharide intercellular adhesin. Infect Immun 62 3244 3253
50. ChristensenGD
BisnoAL
ParisiJT
McLaughlinB
HesterMG
1982 Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis. Ann Intern Med 96 1 10
51. HeilmannC
GerkeC
Perdreau-RemingtonF
GotzF
1996 Characterization of Tn917 insertion mutants of Staphylococcus epidermidis affected in biofilm formation. Infect Immun 64 277 282
52. VuongC
GotzF
OttoM
2000 Construction and characterization of an agr deletion mutant of Staphylococcus epidermidis. Infect Immun 68 1048 1053
53. CDC
2003 Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections—Los Angeles County, California, 2002–2003. MMWR Morb Mortal Wkly Rep 52 88
54. CDC
1999 From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus—Minnesota and North Dakota, 1997-1999. Jama 282 1123 1125
55. PeschelA
OttenwalderB
GotzF
1996 Inducible production and cellular location of the epidermin biosynthetic enzyme EpiB using an improved staphylococcal expression system. FEMS Microbiol Lett 137 279 284
56. VoyichJM
OttoM
MathemaB
BraughtonKR
WhitneyAR
2006 Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease? J Infect Dis 194 1761 1770
57. SreeramaN
WoodyRW
2004 Computation and analysis of protein circular dichroism spectra. Methods Enzymol 383 318 351
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2010 Číslo 10
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Retroviral RNA Dimerization and Packaging: The What, How, When, Where, and Why
- Viral Replication Rate Regulates Clinical Outcome and CD8 T Cell Responses during Highly Pathogenic H5N1 Influenza Virus Infection in Mice
- Antimicrobial Peptides: Primeval Molecules or Future Drugs?
- Crystal Structure of DotD: Insights into the Relationship between Type IVB and Type II/III Secretion Systems